trial · primary record
Rituximab
Pulmonary Alveolar Proteinosis (PAP)
| Phase | Phase 1 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 7 |
| Primary completion | 2021-05-06 |
| Primary endpoint | safe and tolerable administration of rituximab in subjects with anticytokine autoantibody-associated diseases who are refractory to conventional treatment |
| Registry ID | NCT01842386 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:39.697Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT01842386
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.